Table 1.
Preclinical studies of combined gene therapy with co-administration of monocistronic vectors
| Pathology | Therapeutic genes | Animal model | Vector type | Ref. |
| Cancers | ||||
| Leukemia, melanoma | Angiostatin + endostatin | Mouse | Retrovirus | Scappaticci et al[4], 2001 |
| Ovarian cancer | Angiostatin + endostatin | Mouse | AAV | Ponnazhagan et al[3], 2004 |
| Glioblastoma | VEGF-R1 + angio-endo (Statin AE) | Mouse | SB transposon | Ohlfest et al[60], 2005 |
| Pancreatic cancer | TSP1 + endostatin | Mouse | AAV | Zhang et al[61], 2007 |
| Cardiovascular diseases | ||||
| Limb ischemia | VEGFA + angiopoietin-1 | Rabbit | Plasmid | Chae et al[5], 2000 |
| Limb ischemia | VEGFA + FGF2 | Mouse | Plasmid | Lee et al[59], 2007 |
| Limb ischemia | VEGFA + PDGFB | Rabbit | AAV | Kupatt et al[58], 2010 |
| Heart ischemia | VEGFA + PDGFB | Pig | AAV | Kupatt et al[58], 2010 |
| Rear diseases | ||||
| DMD | Microdystrophin + IGF1 | Mouse | AAV | Abmayr et al[62], 2005 |
DMD: Duchenne muscular dystrophy; VEGF: Vascular endothelial growth factor; FGF2: Fibroblast growth factor 2; AAV: Adeno-associated virus.